Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). (Q48067215)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 August 2014

Language	Label	Description	Also known as
English	Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial).	scientific article published on 23 August 2014

Statements

scholarly article

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/25154739

Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). (English)

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/25154739

multicenter clinical trial

1 reference

based on heuristic

inferred from title

object named as

Serenoa repens

1 reference

based on heuristic

inferred from title

Giuseppe Morgia

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Rosalinda Allegro

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Giorgio I Russo

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Salvatore Voce

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Fabiano Palmieri

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Marcello Gentile

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Antonella Giannantoni

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Franco Blefari

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Marco Carini

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Andrea Minervini

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Andrea Ginepri

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Giuseppe Salvia

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Giuseppe Vespasiani

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Giorgio Santelli

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sebastiano Cimino

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Zaira Collura

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Eugenia Fragalà

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Salvatore Arnone

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Rosaria M Pareo

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

publication date

23 August 2014

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/25154739

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

74

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1471-1480

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

The combination of Serenoa repens, selenium and lycopene is more effective than serenoa repens alone to prevent hormone dependent prostatic growth

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

Serenoa Repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

Update on AUA guideline on the management of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

Effect of Serenoa repens, lycopene, and selenium on proinflammatory phenotype activation: an in vitro and in vivo comparison study.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

Do prostatic infarction, prostatic inflammation and prostate morphology play a role in acute urinary retention?

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

A prospective study of lower urinary tract symptoms and erectile dysfunction

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22866

21 January 2018

Identifiers

10.1002/PROS.22866

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25154739%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48067215&oldid=1610914329"